2026-04-04 11:46:51

Anthropic spent $400 million to acquire a company with fewer than 10 employees 🧬

This company is called Coefficient Bio, founded just last year, with a team entirely composed of computational biologists from Genentech.
Spending $400 million on 10 people? Are they crazy?
Not at all. They’re investing in AI + biotech.
Dario (Anthropic CEO)’s ultimate goal is to have Claude participate in drug development. In January, they launched Claude for Life Sciences, integrating research platforms like PubMed and Benchling. Now they’ve also brought people on board.
Basically: AI is no longer just helping you write copy; it’s helping you develop drugs.
There’s a trick here — Anthropic’s IPO is imminent.
Acquiring a biotech team instantly upgrades the valuation narrative: from “chat tool company” to “AI research infrastructure.” The ceiling is completely different.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.